NEW YORK, Feb. 25, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced it was awarded a $2.8 million contract with options for up to $9.9 million from the Department of Defense's Transformational Medical Technologies Initiative (TMTI) through the Defense Threat Reduction Agency (DTRA) to support the preclinical development and Investigation New Drug (IND) filing of ST-669, a broad spectrum antiviral that has demonstrated in vitro antiviral activity against several different viral families. The first contract year provides for $2.8 million of funding with options for additional funding over the following four years, bringing the total value of the contract up to $12.7 million.
